Sugi Predict

Sugi Predict / Compounds / SCHEMBL2931317

SCHEMBL2931317

SCHEMBL2931317

CN1CCN(C(=O)c2ccc(-c3cnc(N)c(-c4cc5ccccc5o4)n3)c(F)c2)CC1

nearest known ligand 0.52

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ MKNK1 Q9BUB5 8/20 0.52
▸ MKNK2 Q9HBH9 8/20 0.52
▸ EIF4E P06730 3/20 0.52
▸ HRH4 Q9H3N8 1/20 0.48
▸ KCNH2 Q12809 1/20 0.46
▸ ATR Q13535 4/20 0.45
▸ MEN1 O00255 1/20 0.44
▸ KMT2A Q03164 1/20 0.44
▸ KDM4E B2RXH2 1/20 0.44
▸ ALDH1A1 P00352 1/20 0.44
▸ LMNA P02545 1/20 0.44
▸ RAB9A P51151 1/20 0.44
▸ ALOX5AP P20292 1/20 0.44
▸ FEN1 P39748 1/20 0.44
▸ HPGD P15428 1/20 0.43
▸ TSHR P16473 1/20 0.43
▸ ADORA2A P29274 1/20 0.43
▸ ADORA1 P30542 1/20 0.43
▸ TNKS O95271 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2925753 0.88 MKNK1 (0.64) MKNK1MKNK2EIF4EHRH4KCNH2
SCHEMBL2927601 0.81 KDR (0.54) HRH4KCNH2ATRMEN1KMT2A
SCHEMBL2933369 0.78 ATR (0.67) MKNK1MKNK2EIF4EKCNH2ATR
SCHEMBL4067706 0.74 ATR (0.51) MKNK1MKNK2EIF4EKCNH2ATR
SCHEMBL1679748 0.72 ATR (0.56) KCNH2ATRKDM4EADORA2ATNKS
SCHEMBL2933842 0.72 ATR (0.56) KCNH2ATRALOX5APFEN1
SCHEMBL2931547 0.71 ATR (0.53) KCNH2ATR
SCHEMBL2933923 0.71 KCNH2 (0.57) MKNK1MKNK2KCNH2ATRALDH1A1
SCHEMBL2932858 0.71 KCNH2 (0.58) KCNH2ATRALOX5APFEN1HPGD
SCHEMBL2933269 0.70 MKNK1 (0.50) MKNK1MKNK2EIF4EKCNH2ATR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2044051-B1 PYRIDINE AND PYRAZINE DERIVATIVES AS MNK KINASE INHIBITORS BIOVITRUM AB PUBL (SE) 2010-01-27 — — EP claimed
EP-2044051-A1 PYRIDINE AND PYRAZINE DERIVATIVES AS MNK KINASE INHIBITORS BIOVITRUM AB (publ) (SE) 2009-04-08 — — EP claimed
US-20080039450-A1 Compounds BIOVITRUM AB (PUBL.) (SE) 2008-02-14 — — US claimed
WO-2007147874-A1 PYRIDINE AND PYRAZINE DERIVATIVES AS MNK KINASE INHIBITORS BIOVITRUM AB (PUBL) (SE) 2007-12-27 — — WO claimed
EP-2044051-B1 PYRIDINE AND PYRAZINE DERIVATIVES AS MNK KINASE INHIBITORS BIOVITRUM AB PUBL (SE) 2010-01-27 — — EP disclosed
EP-2044051-B1 PYRIDINE AND PYRAZINE DERIVATIVES AS MNK KINASE INHIBITORS BIOVITRUM AB PUBL (SE) 2010-01-27 — — EP disclosed
US-20080039450-A1 Compounds BIOVITRUM AB (PUBL.) (SE) 2008-02-14 — — US disclosed
US-20080039450-A1 Compounds BIOVITRUM AB (PUBL.) (SE) 2008-02-14 — — US disclosed
US-20080039450-A1 Compounds BIOVITRUM AB (PUBL.) (SE) 2008-02-14 — — US disclosed
WO-2007147874-A1 PYRIDINE AND PYRAZINE DERIVATIVES AS MNK KINASE INHIBITORS BIOVITRUM AB (PUBL) (SE) 2007-12-27 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080039450-A1 Compounds NEK2, CSNK2A3, CSNK2A1 MKNK1 75/4885MKNK2 39/4885EIF4E 1221/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.